News & Updates

Show Multimedia Only
Osimertinib plus chemo bumps up PFS in advanced EGFR-mutated NSCLC

Osimertinib plus chemo bumps up PFS in advanced EGFR-mutated NSCLC

12 Oct 2023 byJairia Dela Cruz

In the first-line treatment of patients with advanced nonsmall cell lung cancer (NSCLC) harbouring EGFR mutation, the combination of osimertinib plus pemetrexed and platinum-based chemotherapy outperformed osimertinib alone in terms of extending progression-free survival (PFS), according to the interim results of the phase III FLAURA2 trial presented at WCLC 2023.

Osimertinib plus chemo bumps up PFS in advanced EGFR-mutated NSCLC

12 Oct 2023
Do antiemetic drugs prevent chemotherapy-induced nausea, vomiting in cancer patients?

Do antiemetic drugs prevent chemotherapy-induced nausea, vomiting in cancer patients?

11 Oct 2023
ALA-PDT on par with minocycline for moderate-to-severe rosacea

ALA-PDT on par with minocycline for moderate-to-severe rosacea

08 Oct 2023

Patients with moderate-to-severe rosacea may benefit from treatment with 5-aminolevulinic acid photodynamic therapy (ALA-PDT), which has shown its efficacy and noninferiority to minocycline in a recent study.

ALA-PDT on par with minocycline for moderate-to-severe rosacea

08 Oct 2023